2024-04-03 01:10:40 ET
Summary
- Annexon, Inc. is a clinical stage biotech company that is close to releasing topline data on its lead therapy, ANX005.
- ANX005 has the potential to become the first FDA approved therapy for Guillain-Barré syndrome (GBS).
- GBS is a rare disease that affects patients in different ways.
This is my first report on Annexon, Inc. ( ANNX ) a clinical stage biotech. Annexon is on the cusp of delivering top line data on its pivotal trial of its lead therapy in development, ANX005. It strives to be the first FDA approved therapy for Guillain-Barré syndrome [GBS]....
Read the full article on Seeking Alpha
For further details see:
Annexon: Unforced Error Sullies Prospects